The Phase 3 EVOKE study (NCT04777396) investigating semaglutide in people with early Alzheimer's disease completed its primary phase on 2025-09-16. This trial, which enrolled 1840 participants, aimed to determine if semaglutide has a positive effect on the condition.
Background
The EVOKE study is a research initiative to investigate the potential effects of semaglutide in individuals diagnosed with early Alzheimer's disease. This trial explores a novel application for the drug in a challenging neurological condition.
Trial design
The EVOKE study (NCT04777396) is a Phase 3, randomized, placebo-controlled trial. It enrolled 1840 participants with early Alzheimer's disease. Participants were randomly assigned to receive either semaglutide or a placebo, with treatment allocation decided by equal chance. The study is designed to last for up to 173 weeks (about 3 years and 4 months), involving 17 clinic visits and 1 phone call with the study doctor, alongside various tests and scans.
What this means
The primary completion of the Phase 3 EVOKE study marks a significant milestone in the investigation of semaglutide for early Alzheimer's disease. While specific outcomes are not yet available, the completion of this large-scale trial indicates progress in gathering comprehensive data on the drug's potential efficacy and safety profile in this challenging condition. The findings from this study will be crucial for understanding the role semaglutide might play in managing early Alzheimer's disease.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The status update for study NCT04777396, titled "A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)," was posted on 2025-09-16 on clinicaltrials.gov.